August 9th 2020
Adaptive Biotechnologies’ clonoSEQ gets third approval; FDA also acts on first at-home treatment for spinal muscular atrophy.
November 25th 2019
Advancing Precision Care Through Biomarker-Driven Therapy: CEACAM5 as a Therapeutic Target in NSCLC
View More
Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
View More
2023 IASLC North America Conference on Lung Cancer Satellite Symposia
Register Now!
Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care
View More
Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care
View More
Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers
View More
Show Me Your Care Plan™: Monitoring and Managing Patients With EGFR Exon20 Insertion+ NSCLC
View More
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
View More
Community Practice Connections™: 17th Annual New York Lung Cancers Symposium
View More
Trekking Through the Latest Updates for ROS1-Targeted Therapies
View More
Navigating the Latest Data on NTRK-Targeted Therapies
View More
40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC
View More
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
View More
21st Annual Winter Lung Cancer Conference®
Register Now!
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
On-Demand Video Updates from the Annual Oncology Meeting
View More
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
Martin F. Dietrich, MD, PhD; Neil A. Abrahams, MD; Shirley M. Shiller, DO, AP/CP, MGP, FACP
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Register Now!
Radiation Oncology Model: What You Need to Know
November 4th 2019As the proposed Radiation Oncology Model innovative payment model looms on the horizon, Anne Hubbard, director of health policy for the American Society for Radiation Oncology, talks about the main elements and complex finer points of the model, as well as what it will take for its success.
Read More
Planning For Oncology Care Model 2.0 is Underway
October 30th 2019Proposed as an alternative to CMS’ Oncology Care Model, the Community Oncology Alliance is developing its Oncology Care Model 2.0 with the hopes of creating a better, more efficient payment and treatment system for cancer care.
Read More